1. Papur › Ymchwil › Heb ei adolygu gan gymheiriaid
2. Cyhoeddwyd

   Public funding of drugs for orphan diseases

   Hughes, D. & Hughes, D. A., 1 Tach 2005.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   Public meetings of the NICE appraisals committee

   Hughes, D. & Hughes, D. A., 1 Rhag 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Quantitative risk-benefit analysis

   Hughes, D. & Hughes, D. A., 1 Mai 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. Cyhoeddwyd

   Rationing of drugs for rare diseases

   Hughes, D. & Hughes, D. A., 1 Ebr 2006.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

6. Cyhoeddwyd

   Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer

   Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Maw 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

7. Cyhoeddwyd

   The all wales medicines strategy group: assessments and appraisals

   Hughes, D. & Hughes, D. A., 1 Tach 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

8. Cyhoeddwyd

   The assessment, determinants & economics of medication compliance & persistence

   Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Hyd 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

9. Cyhoeddwyd

   The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

   Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Maw 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

10. Cyhoeddwyd

    The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

11. Cyhoeddwyd

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

12. Cyhoeddwyd

    The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

    Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., [. V., Molyneux M.E.*, [. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

13. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Tach 2000.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

14. Cyhoeddwyd

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, [. V., Hughes D.A., [. V. & Pirmohamed, M., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

15. Cyhoeddwyd

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

16. Cyhoeddwyd

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Tach 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

18. Cyhoeddwyd

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, [. V., Salas, M. & Shinogle, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

19. Papur › Ymchwil › Adolygwyd gan gymheiriaid
20. Cyhoeddwyd

    A Systematic Review of Patient Preferences for Subcutaneous Medications

    Ridyard, C., Dawoud, D. & Hughes, D., Tach 2013.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

21. Cyhoeddwyd

    Identification Of Items For A Standardised Resource-Use Measure: Review Of Current Instruments

    Thorn, J. C., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S. & Hollingworth, W., Tach 2015.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

22. Cyhoeddwyd

    Review of the Use of Resource Use Instruments Based on Patient Recall in Relation to Other Methods of Cost Estimation

    Ridyard, C. & Hughes, D., Tach 2013.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

23. Cyhoeddwyd

    Review of the use of resource use instruments based on patient recall in relation to other methods of resource use estimation

    Ridyard, C. & Hughes, D., Tach 2013.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

24. Cyhoeddwyd

    Screening log data can be used to inform protocol modifications, increasing patient recrutiment to a challanging clinical trial

    Blair, J., Awoyale, L., Thornborough, K., Peak, M., Didi, M., Bedson, E., Hughes, D., Ridyard, C., Tat, T. & Gregory, J., Tach 2013.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

25. Murlen › Ymchwil › Adolygwyd gan gymheiriaid
26. Cyhoeddwyd

    Carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients: a UK study (CARIAD)

    Wilkinson, C., Poolman, M., Roberts, J., Wee, B., Hiscock, J., Hughes, D., Nelson, A., Perkins, P., Johnstone, R. P., Reymond, E., Foster, B., O'Connor, J., Jones, S., Hoare, Z., Roberts, R., Byrne, A., Healy, S. & Lewis, P., 1 Medi 2017.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

27. Cyhoeddwyd

    Comparison of regression methods for the cost effectiveness analysis of clinical trials with a small population size: the sycamore and folated trials

    Culeddu, G., Hughes, D. & Welton, N., 10 Gorff 2017.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

28. Cyhoeddwyd

    Core items for a standardised resource-use measure (ISRUM):expert Delphi consensus survey

    Thorn, J., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., 7 Mai 2017, t. P265. 1 t.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

29. Cyhoeddwyd

    Health Economics Analysis Plans: Where Are We Now?

    Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 3 Tach 2016, t. A397. 1 t.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

30. Cyhoeddwyd

    Health economics analysis plans: the current state of play

    Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 7 Mai 2017, t. P144. 1 t.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

31. Cyhoeddwyd

    Patient-level information and costing systems (PLICS) as a source of routinely collected cost data for trial-based economic evaluations

    Ridyard, C. & Hughes, D., 7 Mai 2017, t. P141. 1 t.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

32. Crynodeb › Ymchwil › Adolygwyd gan gymheiriaid
33. Cyhoeddwyd

    Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)

    Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Medi 2017, t. 22-23.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Crynodeb › adolygiad gan gymheiriaid

34. Arall › Ymchwil › Adolygwyd gan gymheiriaid
35. Cyhoeddwyd

    Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa

    Culeddu, G., Brogan, P. A. & Hughes, D., 2021.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Arall › adolygiad gan gymheiriaid

36. Adroddiad Comisiwn › Ymchwil › Heb ei adolygu gan gymheiriaid
37. Cyhoeddwyd

    A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

38. Cyhoeddwyd

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

39. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

40. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

41. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

42. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

43. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

44. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

45. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

46. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

47. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

48. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

49. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

50. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

51. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

52. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

53. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

54. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

55. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

56. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn